

## DAFTAR PUSTAKA

- A. Blair. Jessica M. , Mark A. Webber, Alison J. Baylay, David O. Ogbolu and Laura J. V. Piddock. 2014. *Molecular mechanisms of antibiotic resistance*. Nature Publiser.
- A. Evans, Hamouda, and G.B. Amyes. 2014, *The Rise of Carbapenem-Resistant Acinetobacter baumannii*. Faculty of Life Sciences, University of Manchester, Manchester, UK
- A. P. Magiorakos et. all., 2012, *Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance*, Clin Microbiol Infect.
- Almaghrabi. Mohammed K., Martin R. P. Joseph, Mohammed M. Assiry, and Mohamed E. Hamid. 2017. *Multidrug-Resistant Acinetobacter baumannii: An Emerging Health Threat in Aseer Region, Kingdom of Saudi Arabia*. Hindawi Canadian Journal of Infectious Diseases and Medical Microbiology
- Almsick a. Vincent van Ghebremedhin a. , Beniam , Pfennigwerth b. Niels , Parviz Ahmad-Nejad, 2018, *Rapid detection of carbapenemase-producing Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae using a bioluminescence-based phenotypic method*. Journal of Microbiological Methods
- A. Karuniawati, et al, 2013. *Detection of carbapenemase encoding genes in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011*. Acta Med Indonesia
- Anwar. Muneeza , Ejaz. Hassan, Zafar. Aizza, and Hamid. Hamdan. 2016. *Phenotypic Detection of Metallo-Beta-Lactamases in Carbapenem Resistant Acinetobacter baumannii Isolated from Pediatric Patients in Pakistan*. Journal of Pathogens
- Aoife Howard, Michael O'Donoghue, Audrey Feeney and Roy D. Sleator. 2012. *Acinetobacter baumannii An emerging opportunistic pathogen*. Department of Biological Sciences; Cork Institute of Technology; Bishopstown, Cork, IrelaSnd

- Askin Derya Aybey , Filiz Aksit , Yasemin Oz , , Abdurrahman Kiremitci b , Gul Durmaz . 2011. *Evaluation of an automated system for the detection of carbapenem resistant Acinetobacter baumannii and assessment of metallo- $\beta$ -lactamase production using two different phenotyping methods*. Journal of Microbiological Methods. Turkey
- Bashir D. *et al.*, 2011. *Detection Of Metallo-Beta-Lactamase (MBL) Producing Pseudomonas aeruginosa at A Tertiary Care Hospital in Kashmir*. African Journal of Microbiology Research.
- Bebrone C. 2007. *Metallo-Beta-Lactamases (Classification, Activity, Genetic Organization, Structure, Zinc Coordination) and Their Superfamily*. Biochemical Pharmacology
- Berges L., H. Rodriguez-Villalobos, A. Deplano and M. J. Struelens. 2007. *Prospective Evaluation Of Imipenem/EDTA Combined Disc and Etest for Detection of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa*. Journal of Antimicrobial Chemotherapy Advance
- BioMérieux Inc., Customer Education. 2008. *Vitek 2 Antibiotic Classification and Modes of Action*. Biomerieux, 2013, Vitek 2™ Technology Product Information, Lyon France
- Bonfiglio G., Russo G., Nicoletti G. (2002). *Recent Developments in Carbapenems*. Expert opin. investig. Drugs.
- Brenda A. *et all*, 2011, *How Bacteria Becaome Resistans to antibiotics, Bacterial pathogenesis A molecular Approach*. American Society for Microbiology. USA
- Castilho SRA, Godoy CSdM ,Guilarde AO, Cardoso JL,Andre ´ MCP , Junqueira-Kipnis AP,*et al.* 2017. *Acinetobacter baumannii strains isolated from patients in intensive care units in Goiania, Brazil :Molecular and drug susceptibility profiles*. Juornal PLoSONE12.
- Clinical and Laboratory Standards Institute (CLSI). 2006.. *Performance Standards for Antimicrobial Susceptibility Testing, 16<sup>th</sup> informational supplement*. Clinical and Laboratory Standards Institute. Document M2-A9, Wayne P.A.
- Clinical and Laboratory Standards Institute (CLSI). 2017. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seven*

*Informational Supplement*. CLSI Document M100-S22 Vol 32 No 3. Wayne, PA.: Clinical and Laboratory Standards Institute.

- Cucunawangsih, *et al.* 2015. *Antimicrobial Susceptibility of Multidrug-Resistant Acinetobacter baumannii in a Teaching Hospital: A Two-Year Observation*. Scientific Research Publishing.
- Darbandi M. *et al.*, 2010. *Fabrication of Free-Standing Ultrathin Films of Porous Metal-Organic Frameworks By Liquid-Phase Epitaxy and Subsequent Delamination*. *Physica Status Rapid Research Letters*, Vol. 4 Issue 8-9.
- Dharmawan, *et al.* 2019. *Mekanisme Resistensi Acinetobacter baumannii terhadap Antibiotik Golongan Karbapenem*. *Jurnal Kedokteran Meditek*
- European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017. *EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance*. *European Society of Clinical Microbiology and Infectious Diseases* . Version 2.0, July 2017.
- Frederick S., M.D., 2004, *Anti-infektif therapy*, *Infectious Diseases-A clinical Short Course*, second edition, McGraw-Hill.
- Frere J.M., 1995. *Beta-Lactamases and Bacterial Resistance to Antibiotics*. *Molecular Microbiology*.
- Gallagher J., MacDougall C. 2012. *Antibiotics Simplified, 2<sup>nd</sup> Edition*. United States: David Cella.
- Gillespie S, Bamford K. At a glance 2009. *Mikrobiologi Medis Dan Infeksi*. Ed.3. Jakarta: Erlangga
- Haryanti L., Pudjiadi A.H., Ifran .E.K.B., Thayeb A., Amir I., & Hegar B. 2013. *Prevalens dan Faktor Risiko Infeksi Luka Operasi Pasca-Bedah*. *Sari Pediatri*, Vol. 15(4):207-212.
- Hawkey P. M. & Livermore D.M. 2012. Carbapenem Antibiotics for Serious Infections. *Br. Med. J.*, 344, e3236
- Howard. Aoife, O'Donoghue. Michael, Feeney . Audrey and Roy D. Sleator, 2012, *Acinetobacter baumannii An emerging opportunistic pathogen*. Department of Biological Sciences; Cork Institute of Technology; Bishopstown, Cork,Ireland.

- Ilyas, et al. 2013. *Antibiotic susceptibility of Acinetobacter baumannii strains in a university hospital*. Journal of Clinical and Experimental Investigations
- Jawetz, Melnick, & Adelberg's. 2013, *Medical Microbiology Twenty-Sixth Edition*, The McGraw-Hill, USA
- Kementrian Kesehatan RI (Kemenkes RI), (2012). *Profil Kesehatan Indonesia Tahun 2012*. Jakarta.
- Kyunwon et al., 2003. VIM- and IMP-Type Metallo- $\beta$ -Lactamase Producing *Pseudomonas* spp. and *Acinetobacter* spp. in Korean Hospitals. *Emerging Infectious Diseases*, Vol. 9, No. 7
- L. Silvia M.P., M.D., and Robert A. W., M.D., 2008, *Acinetobacter Infection*, The new england and journal of medicine,;358:1271-81.
- Latania K. Logan, Sumanth Gandra, Anna Trett, Robert A. Weinstein, and Ramanan Laxminarayan. 2018. *Acinetobacter baumannii Resistance Trends in Children in the United States, 1999–2012*. Departments of 1 Pediatrics and 2 Internal Medicine, Division of Infectious Diseases, 3 Section of Pediatric Infectious Diseases, Rush Medical College, Rush University Medical Center, Chicago.
- Latifa. Rini, 2014. *Deteksi Enzim Karbapenemase dan Gen Pengkodonya pada Isolat pseudomonas aeruginosa dan Acinetobacter baumannii Resisten Karbapenem di ICU-RSUPN Cipto Mangunkusumo tahun 2011*. Fakultas kedokteran. Universitas Indonesia
- Lee, K., Lim, Y.S., Yong, D., Yum, J.H., Chong, Y., 2003. *Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase producing isolates of Pseudomonas spp. and Acinetobacter spp.* J. Clin. Microbiol
- Meini M. R, Leticia I., Llarrull, & Alejandro J. Vila, 2016. *Overcoming Differences: The Catalytic Mechanism of Metallo- $\beta$ -Lactamases*, HHS Public Acces, Department of Health and Human Services USA
- Mayasari, E., & Siregar, C. 2015. *Prevalence Of Acinetobacter Baumannii Isolated From Clinical Specimens In Adam Malik Hospital*. Majalah Kedokteran Andalas.

- Mandell, Douglas, and Bennets., 2010, *Molecular Mechanisms of Antibiotic Resistance in Bacteria*, Principles and practice of Infectious diseases.
- Paterson D. L., 2006. *The Epidemiological Profile of Infections With Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter Species*. Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- Paterson D. L., 2005. *Resistance in Gram-Negative Bacteria: Enterobacteriaceae*. Pennsylvania: Elsevier
- Payne D. J. 1993. *Metallo- $\beta$ -lactamases A New Therapeutic Challenge*. Journal of Medical Microbiology.
- Peleg, Anton. Y, et al. 2008. *Acinetobacter baumannii: Emergence of a Successful Pathogen*, Clinical microbiology review
- Pincus T. et al., 2013. *Cognitive and Affective Reassurance and Patient Outcomes in Primary Care: A Systematic Review*. US National Library Of Medicine National Institute of Health
- Prihatini, Aryati, Hetty. 2007. Identifikasi Cepat Mikroorganisme menggunakan Alat Vitek-2 (Rapid Identification of Microorganism by Vitek-2). Indonesian Journal of Clinical Pathology and Medical Laboratory. 13(3):129 -132.
- Qu, T.T., Zhang, J.L., Wang, J., Tao, J., Yu, Y.S., Chen, Y.G., Zhou, J.Y., Li, L.J., 2009. *Evaluation of phenotypic tests for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa strains in China*. J. Clin. Microbio
- Queenan. Anne Marie, and Bush. Karen, 2007. *Carbapenemases: the Versatile  $\beta$  -Lactamases*
- Qureshi Zubair A. et al. 2017. *Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance*. Clinical Infectious Diseases. . Published by Oxford University Press.
- Radji, M., 2011. *Mikrobiologi Panduan Mahasiswa Farmasi & Kedokteran*. Penerbit Buku Kedokteran EGC: Jakarta
- Saad B. Almasaudi. 2016. *Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features*. Saudi Journal of Biological Sciences.

- Safari, M., Mozaffari Nejad, A. S., Bahador, A., Jafari, R., & Alikhani, M. Y. 2015. *Prevalence of ESBL and MBL encoding genes in Acinetobacter baumannii strains isolated from patients of intensive care units (ICU)*. Saudi Journal of Biological Sciences.
- Simo Tchuinte *et al*, 2019. *Phenotypic and molecular characterisations of carbapenem-resistant Acinetobacter baumannii strains isolated in Madagascar*. Antimicrobial Resistance and Infection Control.
- Soekiman, S 2016. *Infeksi nosokomial di rumah sakit*. Jakarta: CV sagung seto.
- Song. Wonkeun *et al.*, 2014, *Combined Use of the Modified Hodge Test and Carbapenemase Inhibition Test for Detection of Carbapenemase-Producing Enterobacteriaceae and Metallo- $\beta$ -Lactamase-Producing Pseudomonas spp.* Department of Laboratory Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital. Korea
- Stefaniuk A. *et al.*, 2015. *Usefulness of CHROMagar Candida Medium, Biochemical Methods – API ID32C and VITEK 2 Compact and Two MALDI-TOF MS Systems for Candida spp. Identification*. Polish Journal of Microbiology 2016, Vol. 65, No 1, 111-114
- Struthers. Keith, 2017, *Clinical Microbiology Second Edition*, CRC Press
- Tognim MCB, Andrade SS, Silbert S, Gales AC, Jones RN, Sader H. *Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program*. Intern J Infect Dis. 2004; 8:284–91
- Tortora G., Funke B. & Case C., 2010. *Microbiology: An Introduction, 10<sup>th</sup> Edition*. San Francisco: Pearson Benjamin Cummings
- V. Miriagou, 2010, *Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues*, Clinical Microbiology and Infection.
- Venty, R. 2014. *Pola Resistensi Acinetobacter Baumannii Yang Diisolasi di Intensive Care Unit (Icu)Rsud Arifin Achmad Provinsi Riau periode 1 Januari Hingga 31 Desember 2014*. Jom FK, Riau.

- World Health Organization. United Nations high-level meeting on antimicrobial resistance. 2016. <http://www.who.int/antimicrobial-resistance/events/UNGA-meeting-amr-sept2016/en/>
- World Health Organization (WHO). (2014). *Antimicrobial Resistance : Global Report on Surveillance*.
- Yong D., Lee K., Yum J. H., Shin H. B., Rossolini G. M. & Chong Y., 2002. *Imipenem-EDTA Disk Method for Differentiation of Metallo- $\beta$ -Lactamase Producing Clinical Isolates of Pseudomonas spp. and Acinetobacter spp.* J. Clin. Microbiol
- Yuan, Wen-Li, et al. 2018. *Sex bias of Acinetobacter baumannii nosocomial infection*. American Journal of Infection Control, elsevier
- Yu-Chi L. et al., 2009. *Differences in Carbapenem Resistance Genes Among Acinetobacter baumannii, Acinetobacter genospecies 3 and Acinetobacter genospecies 13TU in Taiwan*. International Journal of Antimicrobial Agen: (439-443)

## LAMPIRAN

Lampiran 1. Data uji sensitivitas antibiotika golongan karbapenem terhadap bakteri *Acinetobacter baumannii* menggunakan alat Vitek 2 Compact®

NO.	NO. SAMPEL	HASIL VITEK		
		IMIPENEM	MEROPENEM	DORIPENEM
1	2019/06/10	R	R	R
2	2019/06/191	R	R	R
3	2019/06/199	R	R	R
4	2019/06/219	R	R	R
5	2019/07/90	R	R	R
6	2019/07/92	R	R	R
7	2019/07/218	R	R	R
8	2019/07/253	R	R	R
9	2019/07/304	R	R	R
10	2019/07/324	R	R	R
11	2019/07/352	R	R	R
12	2019/08/77	R	R	R
13	2019/08/277	R	R	R
14	2019/08/285	R	R	R
15	2019/08/367	R	R	R
16	2019/09/63	R	R	R
17	2021/08/312	R	R	R
18	2021/08/351	R	R	R
19	2021/08/366	R	R	R
20	2021/08/383	R	R	R
21	2021/08/386	R	R	R
22	2021/08/03.	R	R	R
23	2021/08/20.	R	R	R

Lampiran 2. Data Hasil Uji Konfirmasi Produksi MBL dengan metode *Combine Disk Test (CDT)*



NO.	NO.SAMPEL	UJI CDT zona hambat (mm)		Selisih (mm)	HASIL
		IMI	IMI + EDTA		
1	2019/06/10	9	26	17	Positif MBL
2	2019/06/191	11	14	3	<b>Negatif MBL</b>
3	2019/06/199	10	17	7	Positif MBL
4	2019/06/219	9	26	17	Positif MBL
5	2019/07/90	10	14	4	<b>Negatif MBL</b>
6	2019/07/92	8	16	8	Positif MBL
7	2019/07/218	10	17	7	Positif MBL
8	2019/07/253	10	15	5	<b>Negatif MBL</b>
9	2019/07/304	11	17	7	Positif MBL
10	2019/07/324	8	18	7	Positif MBL



11	2019/07/352	11	26	18	Positif MBL
12	2019/08/77	9	29	18	Positif MBL
13	2019/08/277	9	16	7	Positif MBL
14	2019/08/285	10	16	7	Positif MBL
15	2019/08/367	10	17	7	Positif MBL
16	2019/09/63	10	18	8	Positif MBL
17	2021/08/312	10	18	8	Positif MBL
18	2021/08/351	10	18	8	Positif MBL
19	2021/08/366	10	18	8	Positif MBL
20	2021/08/383	10	29	19	Positif MBL
21	2021/08/386	10	26	16	Positif MBL
22	2021/08/03	10	18	8	Positif MBL
23	2021/08/20	10	19	9	Positif MBL

Keterangan : Perbandingan zona hambat antara disk CDT IMP dengan EDTA+IMP  $\geq 7$  mm dinyatakan sebagai hasil yang positif menghasilkan MBL (Yong, D. *et al*, 2002).

Lampiran 3. Gambar Hasil Pengamatan



## Lampiran 4. Rekomendasi Persetujuan Etik


**KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI**  
**UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN**  
**KOMITE ETIK PENELITIAN KESEHATAN**  
**RSPTN UNIVERSITAS HASANUDDIN**  
**RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR**  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari.,M.Med.,Ph.D., SpGK. TELP. 081241850858, 0411 5780103, Fax : 0411-581431

**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 464/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 21 Juli 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21070439	No Sponsor Protokol	
Peneliti Utama	<b>Muhammad Nur Ajwad</b>	Sponsor	
Judul Peneliti	Gambaran Kejadian Resistensi Acenitobacter baumannii Terhadap Antibiotik Golongan Karbapenem di RSUP Dr. Wahidin Sudirohusodo Makassar		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>12 Juli 2021</b>
No Versi PSP		Tanggal Versi	
Tempat Penelitian	<b>RS Dr. Wahidin Sudirohusodo Makassar</b>		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>21 Juli 2021</b> sampai <b>21 Juli 2022</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## Lampiran 5. Hasil Laboratorium

**HASIL PEMERIKSAAN LABORATORIUM PATOLOGI KLINIK**  
**RSUP DR WAHIDIN SUDIROHUSODO MAKASSAR**  
 Jl. Perintis Kemerdekaan Km. 11, Tamalanrea, Makassar - 90245.  
 Telp. (0411) 584677 psw. 8134, 8127

No. RM	No. Registrasi
Nama	Tgl Registrasi
Jns Kel/Tgl Lahir	Tgl Hasil
No. Lab	Unit Pengantar
Diagnosa	Dokter Perujuk

Diagnosa : RI5076

Hasil Pemeriksaan : **Kultur dan Sensitivitas**  
 Bahan : Pus diabetik  
 Biakan Aerob  
 A. Acinetobacter baumannii  
 B.

Gram  
 A. Bacil gram negatif  
 B. -

Jumlah bakteri/ml Urine:

No	NAMA ANTIBIOTIK	A		B	
		MIC	Interpretasi	MIC	Interpretasi
	Ampicillin	-	-	-	-
	Amoxilin - Clavulanic acid	-	-	-	-
	Piperacillin-Tazobactam	>=128	R	-	-
4	Cefoxitin	-	-	-	-
5	Cefotaxime	>=64	R	-	-
6	Ceftazidime	>=64	R	-	-
7	Ceftriaxone	>=64	R	-	-
8	Cefoperazone-Sulbactam	>=64	R	-	-
9	Doripenem	>=8	R	-	-
10	Imipenem	>=16	R	-	-
11	Meropenem	>=16	R	-	-
12	Amikacin	-	-	-	-
13	Gentamicin	>=16	R	-	-
14	Tobramicin	>=16	R	-	-
15	Levofloxacin	>=8	R	-	-
16	Doxycycline	>=16	R	-	-
17	Polymyxin B	0.5	S	-	-

Keterangan  
 S= Sensitif (peka)      R= Resisten (Kebal)      I=Intermedite  
 MIC = Minimum Inhibitory Concentration (M100)

Resan : XDR  
 Makassar, 27-06-2019 11:05:57

Dokter Perujuk, [Redacted]